EMCM is actively involved in the development of innovative biomaterials which bring together our knowledge in working with collagen molecules & human allografts to provide controlled drug and peptide release profiles via the aforementioned carriers. Our knowledge of working with hydrogels and combinations with the grafts add quite a significant value. This development is being tried across various platforms of controlled release & combinations in the pursuit of opening up new opportunities.

This method in development and subsequent products will benefit from the benefits in safety, cleanliness and mildness that the eCOO® Technology offers in tissue processing, which EMCM continues to explore following its policy of constant innovation.

Due to host material, scientific and technical limitations, all advantages of the eCOO® Technology platform may not be applicable to each product under eTiss®, eColl® & eNova® products.